Paul, Mercy Hospital in Coon Rapids and Hennepin County INFIRMARY in Minneapolis. This extension of CCTRN already has three trials prepared, including An allogeneic mesenchymal cell for sufferers with advanced center function requiring left ventricular assist device; An enhanced autologous bone marrow cell for patients with claudication ; and A combination of a bone marrow cell and a novel cardiac derived cell for individuals with heart failing. ‘These trials will play a key part in identifying the benefits of cell therapy in sufferers with cardiovascular disease. The Minneapolis Heart Institute at Abbott Northwestern Medical center has been a leader in cardiovascular cell therapy analysis with an increase of than 300 sufferers treated for a variety of conditions including acute heart attack, heart failure, ischemic cardiovascular disease and peripheral arterial disease,’ Henry said.The change primarily reflects the amortization of $8.6 million in revenue related to the gain on the sale of the progesterone assets to Watson, the $5.0 million milestone from Watson, and the $2.5 million gain on the sale of STRIANT in the second quarter of 2011, offset, in part, by the $2.4 million upsurge in net item revenues and slight increase in royalty revenues in the next quarter of 2012. Other income and expenditure aggregated to net gain of $0.3 million for the next quarter of 2012, in comparison to $2.6 million in the second quarter of 2011, mainly reflecting the reputation of the $0. As a result, the business reported net gain of $1.9 million, or $0.02 per basic and diluted share, compared to net income of $18.3 million, or $0.21 per simple and $0.16 per diluted share, for the next quarter of 2011.0 million, in comparison to cash, cash equivalents and short-term investments of $22.7 million at March 31, 2012, and $25.1 million at December 31, 2011.